Klotho and vascular calcification

An evolving paradigm

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Cardiovascular disease remains the single most serious contributor to mortality in chronic kidney disease (CKD). Although conventional risk factors are prevalent in CKD, both cardiomyopathy and vasculopathy can be caused by pathophysiologic mechanisms specific to the uremic state. CKD is a state of systemic αKlotho deficiency. Although the molecular mechanism of action of αKlotho is not well understood, the downstream targets and biologic functions of αKlotho are astonishingly pleiotropic. An emerging body of literature links αKlotho to uremic vasculopathy. RECENT FINDINGS: The expression of αKlotho in the vasculature is controversial because of conflicting data. Regardless of whether αKlotho acts as a circulating or resident protein, there are good data associating changes in αKlotho levels with vascular pathology including vascular calcification and in-vitro data of the direct action of αKlotho on both the endothelium and vascular smooth muscle cells in terms of cytoprotection and prevention of mineralization. SUMMARY: It is critical to understand the pathogenic role of αKlotho on the integral endothelium-vascular smooth muscle network rather than each cell type in isolation in uremic vasculopathy, as αKlotho can serve as a potential prognostic biomarker and a biological therapeutic agent.

Original languageEnglish (US)
Pages (from-to)331-339
Number of pages9
JournalCurrent Opinion in Nephrology and Hypertension
Volume23
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Vascular Calcification
Chronic Renal Insufficiency
Vascular Smooth Muscle
Endothelium
Cytoprotection
Cell Separation
Biological Factors
Cardiomyopathies
Smooth Muscle Myocytes
Blood Vessels
Cardiovascular Diseases
Biomarkers
Pathology
Mortality
Proteins
Therapeutics

Keywords

  • Chronic kidney disease
  • Endothelium
  • Vascular calcification
  • Vascular smooth muscle cells
  • αKlotho

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Klotho and vascular calcification : An evolving paradigm. / Hu, Ming C; Kuro-o, Makoto; Moe, Orson W.

In: Current Opinion in Nephrology and Hypertension, Vol. 23, No. 4, 2014, p. 331-339.

Research output: Contribution to journalArticle

@article{58c46371a5ca498a9da61885f41eed79,
title = "Klotho and vascular calcification: An evolving paradigm",
abstract = "Cardiovascular disease remains the single most serious contributor to mortality in chronic kidney disease (CKD). Although conventional risk factors are prevalent in CKD, both cardiomyopathy and vasculopathy can be caused by pathophysiologic mechanisms specific to the uremic state. CKD is a state of systemic αKlotho deficiency. Although the molecular mechanism of action of αKlotho is not well understood, the downstream targets and biologic functions of αKlotho are astonishingly pleiotropic. An emerging body of literature links αKlotho to uremic vasculopathy. RECENT FINDINGS: The expression of αKlotho in the vasculature is controversial because of conflicting data. Regardless of whether αKlotho acts as a circulating or resident protein, there are good data associating changes in αKlotho levels with vascular pathology including vascular calcification and in-vitro data of the direct action of αKlotho on both the endothelium and vascular smooth muscle cells in terms of cytoprotection and prevention of mineralization. SUMMARY: It is critical to understand the pathogenic role of αKlotho on the integral endothelium-vascular smooth muscle network rather than each cell type in isolation in uremic vasculopathy, as αKlotho can serve as a potential prognostic biomarker and a biological therapeutic agent.",
keywords = "Chronic kidney disease, Endothelium, Vascular calcification, Vascular smooth muscle cells, αKlotho",
author = "Hu, {Ming C} and Makoto Kuro-o and Moe, {Orson W}",
year = "2014",
doi = "10.1097/01.mnh.0000447024.97464.a3",
language = "English (US)",
volume = "23",
pages = "331--339",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Klotho and vascular calcification

T2 - An evolving paradigm

AU - Hu, Ming C

AU - Kuro-o, Makoto

AU - Moe, Orson W

PY - 2014

Y1 - 2014

N2 - Cardiovascular disease remains the single most serious contributor to mortality in chronic kidney disease (CKD). Although conventional risk factors are prevalent in CKD, both cardiomyopathy and vasculopathy can be caused by pathophysiologic mechanisms specific to the uremic state. CKD is a state of systemic αKlotho deficiency. Although the molecular mechanism of action of αKlotho is not well understood, the downstream targets and biologic functions of αKlotho are astonishingly pleiotropic. An emerging body of literature links αKlotho to uremic vasculopathy. RECENT FINDINGS: The expression of αKlotho in the vasculature is controversial because of conflicting data. Regardless of whether αKlotho acts as a circulating or resident protein, there are good data associating changes in αKlotho levels with vascular pathology including vascular calcification and in-vitro data of the direct action of αKlotho on both the endothelium and vascular smooth muscle cells in terms of cytoprotection and prevention of mineralization. SUMMARY: It is critical to understand the pathogenic role of αKlotho on the integral endothelium-vascular smooth muscle network rather than each cell type in isolation in uremic vasculopathy, as αKlotho can serve as a potential prognostic biomarker and a biological therapeutic agent.

AB - Cardiovascular disease remains the single most serious contributor to mortality in chronic kidney disease (CKD). Although conventional risk factors are prevalent in CKD, both cardiomyopathy and vasculopathy can be caused by pathophysiologic mechanisms specific to the uremic state. CKD is a state of systemic αKlotho deficiency. Although the molecular mechanism of action of αKlotho is not well understood, the downstream targets and biologic functions of αKlotho are astonishingly pleiotropic. An emerging body of literature links αKlotho to uremic vasculopathy. RECENT FINDINGS: The expression of αKlotho in the vasculature is controversial because of conflicting data. Regardless of whether αKlotho acts as a circulating or resident protein, there are good data associating changes in αKlotho levels with vascular pathology including vascular calcification and in-vitro data of the direct action of αKlotho on both the endothelium and vascular smooth muscle cells in terms of cytoprotection and prevention of mineralization. SUMMARY: It is critical to understand the pathogenic role of αKlotho on the integral endothelium-vascular smooth muscle network rather than each cell type in isolation in uremic vasculopathy, as αKlotho can serve as a potential prognostic biomarker and a biological therapeutic agent.

KW - Chronic kidney disease

KW - Endothelium

KW - Vascular calcification

KW - Vascular smooth muscle cells

KW - αKlotho

UR - http://www.scopus.com/inward/record.url?scp=84902294428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902294428&partnerID=8YFLogxK

U2 - 10.1097/01.mnh.0000447024.97464.a3

DO - 10.1097/01.mnh.0000447024.97464.a3

M3 - Article

VL - 23

SP - 331

EP - 339

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 4

ER -